data analysis software unix sas version 9.1.3 (SAS institute)
SAS institute is a verified supplier 
90
Structured Review
SAS institute
data analysis software unix sas version 9.1.3
Data Analysis Software Unix Sas Version 9.1.3, supplied by SAS institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/data+analysis+software+unix+sas+version+9%2E1%2E3/data+analysis+software+unix+sas+version+9+1+3/pm24283931-80-1-5
Average 90 stars, based on 1 article reviews
Data Analysis Software Unix Sas Version 9.1.3, supplied by SAS institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/data+analysis+software+unix+sas+version+9%2E1%2E3/data+analysis+software+unix+sas+version+9+1+3/pm24283931-80-1-5
Average 90 stars, based on 1 article reviews
data analysis software unix sas version 9.1.3 - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
other:Article Title: Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. Article Snippet: We used the Article Title: The efficacy and safety of etanercept when used with as-needed adjunctive topical therapy in a randomised, double-blind study in subjects with moderate-to-severe psoriasis (the PRISTINE trial). Article Snippet: Objective: To assess the efficacy and safety of two etanercept dose regimens for psoriasis treatment.. Methods: Subjects were ‡18 years old with stable moderate-to-severe plaque psoriasis.. Subjects were randomised to etanercept 50 mg once weekly (QW) or 50 mg twice weekly (BIW) double-blind for 12 weeks, followed by 50 mg QW open label in all subjects through week 24. Article Title: Improvement in aspects of sleep with etanercept and optional adjunctive topical therapy in patients with moderate-to-severe psoriasis: results from the PRISTINE trial. Article Snippet: Background Impaired sleep in patients with moderate-to-severe psoriasis and improvement on therapy has not been widely studied.. Objective Quantify baseline aspects of sleep and improvement in patients with psoriasis receiving etanercept (ETN) when allowed concomitant topical medications (PRISTINE study).. Methods Patients with moderate-to-severe psoriasis were randomized to 50 mg ETN once weekly (QW/QW) or 50 mg ETN twice weekly (BIW/QW) for weeks 1–12, followed by 50 mg QW for weeks 13–24; a broad range of topical therapies were permitted during weeks 13–24. Article Title: Cardiometabolic profile, clinical features, quality of life and treatment outcomes in patients with moderate-to-severe psoriasis and psoriatic arthritis. Article Snippet: Cardiometabolic, clinical and quality-of-life (QoL) measures were assessed before and after etanercept treatment in patients who had moderate-to-severe plaque psoriasis with and without psoriatic arthritis (PsA) in the PRISTINE trial.. Adult patients were randomized to receive etanercept 50 mg once weekly or twice weekly double-blind for 12 weeks; all patients subsequently received etanercept 50 mg once weekly open-label through week 24.. Metabolic syndrome was identified in 44 and 41% of patients with and without PsA, elevated blood pressure in 73 and 56% (p50.05) and diabetes in 21 and 9% (p50.01), respectively. |